Ifetayo Harvey, Fordham Law Review This Essay calls for a reimagining of how the United States approaches drug policy, starting with the abolition of the DEA. In making the case for abolition, this Essay will proceed in three parts. First, Part I will provide a brief history of the DEA and its mandate as prescribed…
Introducing Petrie-Flom’s POPLAR and PULSE Affiliated Researchers on Psychedelics
Bill of Health // Petrie-Flom Center The Petrie-Flom Center is excited to announce our affiliated researchers for the Project on Psychedelics Law and Regulation (POPLAR) and our new project, Psychedelic Use, Law, and Spiritual Experience (PULSE). Through research, writing, workshops, and other projects, POPLAR and PULSE affiliated researchers will provide expertise and a range of perspectives on psychedelics law and policy. We look forward to learning from them and sharing their…
Psychedelic therapies: healing for the wrong reasons?
Eduardo Schenberg, Christine Hauskeller, Claudia Gertraud Schwarz, and Franklin King IV, Nature Mental Health When critically examining the assertion that biomedical treatments work for the ‘right’ reasons compared with alternative approaches, philosopher of science Isabelle Stengers1 coined the phrase ‘healing for the wrong reasons’. Here, we discuss the cognitive dissonances and regulatory misalignments apparent in the…
State Drug Laws
Mason Marks, Fordham Law Review This Essay provides a typology of state drug laws comprising thirteen categories, including decriminalization, recriminalization, adult use, supported adult use, medical use, supported medical use, religious use, social consumption, safe consumption, clinical research, policy analysis, trigger laws, and food and agricultural laws. Several states have enacted hybrid legislation that blends…
Momentum is Not Enough: A Call for Consistency in Psychedelic Legislation
Bill of Health // Petrie-Flom Center By Karina Bashir….
FDA rejects ecstasy as a therapy: what’s next for psychedelics?
Nature // Petrie-Flom Center Following the US drug agency’s decision, Nature examines the outlook for other hallucinogens that are in clinical trials as psychiatric treatments. By Sara Reardon, featuring I. Glenn Cohen and Mason Marks….
FDA rejected MDMA-assisted PTSD therapy. Other psychedelics firms intend to avoid that fate
Science // Petrie-Flom Center Lykos Therapeutics’s failure to win approval may trigger a strategic shift in psychedelic medicine. By Kai Kupferschmidt, featuring I. Glenn Cohen….
Getting to ‘Plan B’ for psychedelic medicine: Lessons from reproductive health
STAT // Petrie-Flom Center The Food and Drug Administration’s decision not to approve Lykos Therapeutics’ application for MDMA (a psychedelic drug known on the street as ecstasy or molly) plus therapy for post-traumatic stress disorder comes as no surprise, given an advisory panel’s “no” vote on the application in June. But if lessons from reproductive…
Psychedelic Therapy Scrutinized by FDA Advisory Committee?
Mason Marks, JAMA Network…
Psychedelics for Healing
Harvard Magazine // Petrie-Flom Center Harvard’s I. Glenn Cohen on the use of “magic mushrooms” and other psychedelics in medicine, by Olivia Farrar….